Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details

Published

on

Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Shares of Wockhardt soared as much as 19% to their day’s high of Rs 2,420 on the BSE on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.

According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.

The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year.

The company also noted that complicated urinary tract infections account for more than 6,00,000 hospitalisations annually in the U.S., with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria.

Advertisement

The FDA’s decision was based in part on results from the Phase 3 ENHANCE-1 study, a randomised, double-blind, multicentre trial that evaluated the efficacy, safety and tolerability of ZAYNICH against meropenem in hospitalised adults with complicated urinary tract infections or acute pyelonephritis.


Also read: FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem. The treatment difference was 20.6% with a 95% confidence interval of 12.3 to 29.5. The company said the drug was generally well tolerated during the trial.The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India.

Wockhardt stated that ZAYNICH targets penicillin-binding proteins PBP 1a/b, 2 and 3 simultaneously, a mechanism that it says provides bactericidal activity against multidrug-resistant Gram-negative bacteria for which treatment options remain limited.

The company also disclosed that ZAYNICH received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. In addition, Wockhardt has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the antibiotic.

Sensex, Nifty today: Catch all the LIVE stock market action here
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

You Could Get Lost in Space Using These Funds

Published

on

You Could Get Lost in Space Using These Funds

You Could Get Lost in Space Using These Funds

Continue Reading

Business

Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis

Published

on

Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis

Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis

Continue Reading

Business

Market Fear Index Drops as Investors Hope for Iran Deal

Published

on

Barron's

Wall Street’s go-to fear gauge was sliding on Friday, signaling that investors were feeling a little calmer after President Donald Trump called off planned U.S. strikes on Iran.

The Cboe Volatility Index, or VIX, slipped 0.9 points to 18.5 in early trading. Any reading below 20 tends to indicate relatively low volatility.

The VIX was moving lower after Trump canceled attacks on Iran and signaled there could soon be a peace deal to end the war in the Middle East. That put the market at ease–although volatility could flare up again later if SpaceX’s trading debut doesn’t go to plan.

Continue Reading

Business

Weekly Indicators: Consumers Back Off – Slightly

Published

on

Weekly Indicators: Consumers Back Off - Slightly

Weekly Indicators: Consumers Back Off – Slightly

Continue Reading

Business

Premium Brands: The M&A Flywheel Is Spinning Again

Published

on

Premium Brands: The M&A Flywheel Is Spinning Again

Premium Brands: The M&A Flywheel Is Spinning Again

Continue Reading

Business

Pakistan PM says US-Iran peace deal signing expected within 24 hours

Published

on

Pakistan PM says US-Iran peace deal signing expected within 24 hours


Pakistan PM says US-Iran peace deal signing expected within 24 hours

Continue Reading

Business

LandBridge: The Landlord Quietly Cashing In On Oil, Water And Data Centers (NYSE:LB)

Published

on

LandBridge: The Landlord Quietly Cashing In On Oil, Water And Data Centers (NYSE:LB)

This article was written by

I am a lawyer with a strong personal interest in investing and fundamental equity research. Over time, I developed a particular interest in small-cap companies, where I believe careful analysis can uncover businesses that are still misunderstood, underfollowed, or mispriced by the market. My goal is to identify companies with attractive long-term potential, solid business models, and a margin of safety that may not be fully reflected in their current valuation.My professional background in law has shaped the way I approach investment research. Legal training requires close reading, attention to detail, disciplined reasoning, and the ability to evaluate risk from multiple angles. I bring that same mindset to investing, particularly when analyzing corporate filings, disclosures, governance issues, business quality, and management communication. I am especially interested in understanding not only what a company reports, but also how its strategy, incentives, and risk profile may affect long-term shareholder outcomes.I am writing on Seeking Alpha because I enjoy the research process and value the opportunity to share ideas with a serious investing community. Writing helps me refine my own thinking, test my investment theses, and engage with other investors who also appreciate disciplined, independent analysis.Closely associated with Rafael Binatti Costa.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Teladoc stock surges 69% after Fair Value models spotted opportunity

Published

on


Teladoc stock surges 69% after Fair Value models spotted opportunity

Continue Reading

Business

The Questions Chairman Warsh Must Answer

Published

on

The Questions Chairman Warsh Must Answer

The Questions Chairman Warsh Must Answer

Continue Reading

Business

The 14% burger tax: How BBQ inflation hits your wallet this summer

Published

on

The 14% burger tax: How BBQ inflation hits your wallet this summer

Hard-working Americans looking to fire up the grill this weekend are facing major sticker shock before they even light the charcoal.

As inflation continues to squeeze household budgets, the newly released Wells Fargo summer BBQ food report reveals that hosting a standard summer barbecue for 10 people has climbed to an average of $161 — or about $16 per person.

Advertisement

While total cookout costs are up 2.4% year over year, the real pricing pain is hiding right on the meat tray: the quintessential American hamburger beef has skyrocketed by 14%.

“Regarding food inflation, price increases this season will really depend on the category. For fresh fruits and vegetables, we anticipate some relief as summer unfolds. 

Growers are motivated by higher prices to plant more acreage, so increased supply should help moderate price hikes and may actually offer consumers a bit of a break,” Wells Fargo Agri-Food Institute head Robin Wenzel told Fox News Digital.

WALMART WARNS SHOPPERS COULD FACE HIGHER PRICES AS FUEL COSTS SURGE, TAX REFUNDS DRY UP

Advertisement

“However, for those who value convenience and opt for prepared foods, expect prices to edge up,” she warned.

 “These items are driven more by labor, packaging and energy costs than the underlying commodities themselves. As consumers continue to pay for convenience, retailers are able to maintain their margins with higher pricing.”

Woman shops for meat at grocery store

Red meat is displayed at a grocery store in Brooklyn on May 12, 2026, in New York City. (Getty Images)

Though burgers are taking the biggest hit from inflation, so are other grilling favorites. Chicken and pork products rose 3% from the previous year and are seen as the “cost-friendly” option, while hot dogs and frankfurters are up 5%.

Ready-made sides like potato salad are up 3% because of higher manufacturing wages being passed on to consumers, the report notes. Other favorites like cornbread are up 4%, raw vegetables are up 6%, and if you’re saving room for dessert, sweet-treat prices have increased anywhere from 1% to 4%.

Advertisement

The higher price tags fall in line with the May consumer price index (CPI) – a broad measure of how much everyday goods like gasoline, groceries and rent cost – which rose 0.5% in May and 4.2% from a year earlier. The annual figure is the highest since April 2023.

Pre-made grocery store shortcuts can be a budget-buster during the summer, as buying a pre-cut vegetable tray adds a $7 premium to your bill, while buying fully cooked, pre-packaged ribs costs $4 more per pound than buying them raw.

“Hosts can save by preparing ribs from scratch, allowing a bit more room to indulge in prepared veggie trays if desired,” Wenzel said. “Budget-conscious hosts should thoughtfully weigh where to splurge. While pre-cooked ribs are more expensive, pork still offers a better value than beef, which remains a costly grill option.”

Advertisement

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Asked to craft the best “inflation-busting” menu, Wenzel recommended serving up chicken, pork, made-from-scratch sides like deviled eggs (eggs are down 14%), watermelon, strawberries (both fruits are down 3%) and cookies or ice cream for dessert.

“When hosting a BBQ for 10 on a strict budget, plan wisely with proteins and look for value where it counts… the decision between homemade and prepared foods is key. Making from scratch, such as potato salad can save money, but convenience has its place,” Wenzel said. “Beer and wine prices haven’t climbed much, but they’ll still add to the total, so asking guests to BYOB is a smart way to keep costs down.”

Advertisement

READ MORE FROM FOX BUSINESS

FOX Business’ Eric Revell contributed to this report.

Continue Reading

Trending

Copyright © 2025